<DOC>
	<DOCNO>NCT03036501</DOCNO>
	<brief_summary>This open-label , non-randomized study investigate excretion balance , PK metabolism single oral dose [ 14C ] -labeled RO7034067 healthy male participant . This study ass characterize mass balance , rout rate elimination [ 14C ] -labeled RO7034067 , use conventional analytical method ass pharmacokinetics total drug relate [ 14C ] -radioactivity , RO7034067 metabolite ( ) .</brief_summary>
	<brief_title>A Study Investigating Excretion Balance , Pharmacokinetics Metabolism Single Oral Dose 14C-Labeled RO7034067 Healthy Male Participants</brief_title>
	<detailed_description />
	<criteria>Healthy male participant , 35 65 year age ( inclusive ) A body mass index 18 30 kg/m^2 inclusive Agreement use two method contraception , treatment period least 4 month last dose study drug . One contraceptive method must condom . The second contraceptive method must include one follow : diaphragm cervical cap , intrauterine device system , oral , injected implant hormonal method contraception . No intention donate sperm within 4 month study drug administration Able participate willing give write informed consent comply study requirement restriction Fluent language Investigator study staff able communicate study staff Any condition disease detect medical interview/physical examination would render participant unsuitable study , place participant undue risk interfere ability participant complete study opinion Investigator History clinically significant gastrointestinal , renal , hepatic , broncho pulmonary , neurological , psychiatric , cardiovascular , endocrinological , hematological allergic disease , metabolic disorder , hypofertility , cancer cirrhosis Participants clinically significant eye pathology affect bestcorrected visual acuity , optic neuritis retinal abnormality spectral domain optical coherence tomography 7field fundus color photography assess ophthalmologist History evidence ( neuro ) muscular disorder History evidence medical condition potentially alter absorption , metabolism elimination drug . Surgical history gastrointestinal tract affect gastric motility alter gastrointestinal tract History evidence skin disorder , assess thorough skin examination whole body History malignancy past 5 year A history clinically significant hypersensitivity ( e.g. , drug , excipients ) allergic reaction Participants , Investigator 's judgment , pose suicidal homicidal risk , participant history suicidal homicidal attempt Any major illness within one month screen examination febrile illness within one week prior screen study drug administration History presence clinically significant ECG abnormality study drug administration cardiovascular disease Clinically significant abnormality laboratory test result Positive result test human immunodeficiency virus ( HIV ) 1 HIV2 , hepatitis C virus hepatitis B virus Any suspicion history alcohol abuse and/or suspicion regular consumption drug abuse Confirmed systolic blood pressure ( SBP ) great 150 less 90 mmHg , diastolic blood pressure ( DBP ) great 95 less 50 mmHg Confirmed ( base average least 3 consecutive measurement ) rest pulse rate great 100 less 40 bpm Participation investigational drug device study within 90 day prior screen , calculate day followup previous study Smokers regularly smoke 10 cigarette daily equivalent tobacco contain product Dietary restriction would prohibit consumption standardize meal Use prohibit medication food study start study Participants judicial supervision , guardianship curatorship Infrequent bowel movement ( less per 24 hour average ) Regular work ionize radiation radioactive material Participants plan attempt father child within 4 month study drug administration</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>